Second Once-Weekly Insulin Approved for Type 2 Diabetes

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

Onswik Once-Weekly Insulin Approved for Type 2 Diabetes

On Sept. 23, 2026, the US Food and Drug Administration (FDA) approved Eli Lilly’s Onswik™ (insulin efsitora alfa-gobe), the second once‑weekly long‑acting basal insulin analog, for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Onswik is not recommended for use in patients who have type 1 diabetes mellitus due to an increased risk of severe hypoglycemia. Onswik provides continuous basal insulin coverage with a single weekly subcutaneous (SC) injection into the abdomen, upper arm, thigh or buttocks. The recommended dose is individualized based on metabolic needs, blood glucose monitoring results and glycemic control goals; it is administered on the same day each week. Onswik KwikPens will be supplied as 3mL prefilled pens in 500units/mL and 1,000units/mL concentrations in the coming months. Approval was supported by the QWINT phase III program, which is made up of four randomized trials in approximately 3,400 adults with type 2 diabetes and showed that once‑weekly Onswik was as effective as daily basal insulin in achieving glycemic control. Onswik showed a safety profile similar to daily basal insulins. It will compete with Novo Nordisk’s Awiqli® (insulin icodec‑abae), the first once-weekly long-acting basal insulin, which was approved in March 2026. Here is the full prescribing information for Onswik.

New Indication for Aqneursa Marks First FDA-Approved Treatment for Ataxia-Telangiectasia

On Sept. 18, 2026, the FDA approved a new indication for IntraBio’s Aqneursa® (levacetylleucine) oral suspension for the treatment of ataxia in adult and pediatric patients who have ataxia-telangiectasia (A-T) weighing at least 15kg (33 pounds). Aqneursa is the first FDA-approved therapy specifically indicated for A-T, a rare, inherited neurodegenerative disorder caused by mutations in the ATM gene that results in progressive loss of coordination and muscle control (ataxia) beginning in early childhood, alongside immune deficiencies and an increased risk of certain cancers. Approval was supported by a randomized, double-blind, placebo-controlled crossover study in 73 patients aged 4 years and older with confirmed A-T, in which treatment with Aqneursa resulted in statistically significant improvements in neurological function as measured by the functional Scale for Assessment and Rating of Ataxia (fSARA) compared with placebo. Additional analyses demonstrated improvement across gait, sitting, stance, and speech domains, with clinical benefit observed within 12 weeks of treatment. This is the product’s second approved indication, following its September 2024 approval for the neurological manifestations of Niemann-Pick disease type C (NPC). The recommended dose is weight-based and administered orally two to three times daily as a reconstituted suspension. Here is the updated prescribing information.

FDA Expands Inluriyo Label With Verzenio Combination Approval

The FDA granted full approval of Eli Lilly’s Inluriyo® (imlunestrant) in combination with Verzenio® (abemaciclib) on Sept. 18, 2026, for adults who have estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test, whose disease has progressed following at least one line of endocrine therapy. Inluriyo, an oral estrogen receptor antagonist, was previously granted accelerated approval as monotherapy for this biomarker-defined population in September 2025. This current approval expands its use in combination with Verzenio, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Approval was based on results from the phase III EMBER-3 trial, in which median progression-free survival was 11.1 months with Inluriyo plus Verzenio compared with 5.5 months with Inluriyo alone, representing a 47% reduction in the risk of disease progression or death. Objective response rates were 35% and 15%, respectively. The FDA also approved Guardant360 CDx as a companion diagnostic to identify eligible patients with ESR1 mutations. The recommended doses are Inluriyo 400mg orally once daily on an empty stomach and Verzenio 150mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. Label warnings and precautions include embryo-fetal toxicity for Inluriyo and diarrhea, neutropenia, interstitial lung disease or pneumonitis, hepatotoxicity, venous thromboembolism and embryo-fetal toxicity for Verzenio. The updated prescribing information may be found here for Inluriyo and Verzenio.

Welireg Plus Lenvima Approved for Previously Treated Advanced Clear Cell Renal Cell Carcinoma

On Sept. 24, 2026, the FDA approved Merck’s Welireg® (belzutifan) in combination with Eisai’s Lenvima® (lenvatinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following treatment with a programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor. Welireg is an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor previously approved as monotherapy for previously treated advanced RCC and as part of an adjuvant regimen with Keytruda® (pembrolizumab – Merck). Lenvima is an oral multi-targeted tyrosine kinase inhibitor that is approved in combination with Keytruda for first-line advanced RCC and with everolimus following prior anti-angiogenic therapy. The Welireg plus Lenvima regimen is the first FDA-approved combination of a HIF-2α inhibitor and a vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor for RCC. Approval was based on results from the phase III LITESPARK-011 trial, in which Welireg plus Lenvima significantly improved progression-free survival versus cabozantinib, reducing the risk of disease progression or death by 26% and achieving a median progression-free survival of 14.6 months versus 10.6 months, respectively. The recommended dose is Welireg 120mg orally once daily plus Lenvima 20mg orally once daily until disease progression or unacceptable toxicity. The updated prescribing information can be found here for Welireg and Lenvima.

Bravnetsa, Generic to Lutathera, Joins Bexlutry in Expanding GEP-NET Treatment Options

On Sept. 22, 2026, the FDA granted final approval to Lantheus Holdings’ Bravnetsa™ (lutetium Lu 177 dotatate) for the treatment of adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors. Bravnetsa is a radiopharmaceutical the FDA has determined to be bioequivalent and therapeutically equivalent to Novartis’ Lutathera® (lutetium Lu 177 dotatate), approved through the FDA’s Abbreviated New Drug Application (ANDA) pathway, the traditional generic-drug route, in which a manufacturer demonstrates bioequivalence to an already-approved reference product rather than running new clinical trials. By contrast, Curium’s Bexlutry™, approved on Sept. 14, 2026, used the FDA’s 505(b)(2) pathway, which allows a sponsor to rely partly on the FDA’s prior safety and efficacy findings for Lutathera while still submitting its own supporting data. In practice, this means Bravnetsa is a true, substitutable generic, while Bexlutry is a branded “radioligand equivalent” that competes alongside Lutathera and Bravnetsa but isn’t classified the same way for pharmacy-level substitution purposes. Approval of both follow-on products rested on bioequivalence and comparative data rather than new pivotal efficacy trials. Lantheus indicated it is building out commercial and operational infrastructure to support a “thoughtful launch” and reliable supply. Here is the prescribing information.

FDA Adds Data to Winrevair Label Supporting Use Earlier in PAH Disease Course

The FDA approved an update to the label for Merck’s Winrevair™ (sotatercept-csrk) for injection (45mg, 60mg) on Sept. 22, 2026, to include efficacy and safety data from the phase III HYPERION trial. The label update does not add a new indication but broadens the evidence base to patients earlier in their disease course. Winrevair, an activin signaling inhibitor, remains approved for adults with pulmonary arterial hypertension (PAH) to improve exercise capacity and WHO functional class (FC) and to reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation, and death. HYPERION evaluated adults newly diagnosed with PAH (WHO Group 1) within the past 12 months and showed that adding Winrevair to background therapy in patients with WHO FC II or III PAH reduced the risk of clinical worsening events by 76% versus placebo, with a first worsening event occurring in 10.6% of patients receiving Winrevair compared with 36.9% of those receiving placebo. Updated prescribing info may be found here.

Recall

LubriFresh PM Nighttime Ointment Recalled

Sterling Pharmaceuticals initiated a recall of LubriFresh™ P.M. Nighttime Ointment (mineral oil 15%, white petrolatum 83%) due to certain FDA-observed current manufacturing deficiencies that may affect sterility. Although no confirmed sterility failures or evidence of microbial contamination have been identified in the affected lot, using ophthalmic products with sterility that cannot be fully assured may pose a risk of ocular infection. LubriFresh P.M. Nighttime Ointment is an over-the-counter ophthalmic lubricant indicated for temporary relief of eye dryness and irritation and for protection against further irritation. For more information, see here.